文献速递胸部肿瘤

非小细胞肺癌与多灶性细支气管肺泡细胞癌的肺移植

Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma.
PubMed 文献 · Lancet Oncol · 2018-06-29

本文综述了肺移植用于原发性支气管肺癌的适应证、经验与结局。支气管恶性肿瘤占美国1987至2010年全部肺移植的0·13%,仅适用于因肺功能差而无法手术的早期患者;部分患者可获长期生存,但缺乏头对头试验,供肺分配伦理问题未解。

要点

  • 肺移植用于肺癌属罕见适应证,仅占美国1987至2010年全部肺移植的0·13%
  • 仅限早期、常规手术因肺功能差而禁忌且短期死亡风险高的患者
  • 移植后早期可因远处转移死亡,之后长期生存与其他适应证移植相似

核心结论

  • 肺移植对部分早期支气管肺癌患者可能延长生存并改善生活质量,但证据有限且供肺分配伦理问题未解。

研究设计与样本

  • 本文为综述,分析肺移植用于原发性支气管肺癌的经验、结局及固有局限,未报告系统检索范围。

主要发现

  • 支气管恶性肿瘤占美国1987至2010年全部肺移植的0·13%,属罕见适应证。
  • 在移植肺中意外发现恶性肿瘤时,约30%受者(取决于分期)在移植后最初几年死于远处转移,此后长期生存与其他疾病移植相似。
  • 多灶性细支气管肺泡细胞癌移植时须防止供肺上气道残留癌细胞污染。

关键数值与推荐

  • 肺移植仅适用于早期支气管肺癌且常规手术因肺功能差而禁忌、预期短期死亡风险高者。
  • 移植肺意外发现恶性肿瘤者约30%于移植后最初几年死于远处转移,比例取决于分期。

临床怎么用

  • 对早期肺癌且常规手术因肺功能差而不可行者,可个体化评估肺移植并告知早期远处转移风险。

局限性

  • 肺移植用于癌症罕见,且无肺移植与常规肿瘤治疗的头对头试验,结论受限。
  • 供肺为稀缺资源,长期生存不确定使分配伦理平衡悬而未决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung transplantation for primary bronchogenic cancer could lead to increased survival and improved quality of life for patients who have malignant disease, for which other therapies might be inappropriate. This Review examines the development of experience and outcomes for this indication and explores the limitations that are inherent in lung transplantation for malignant disease. Bronchogenic malignancy is a rare indication for lung transplantation constituting only 0·13% of all lung transplants in the USA from 1987 to 2010 and is only indicated for early-stage disease when conventional surgical techniques are contraindicated by poor lung function in which an unacceptably high risk of short-term mortality is expected. Outcomes can be extrapolated from the experience of finding an unexpected malignancy in an explanted lung for which approximately 30% of recipients, dependent on stage, succumb from distant metastatic disease in the first few years after transplant, after which long-term survival is similar to transplantation for other conditions. Care must be taken for lung transplantation for multifocal bronchoalveolar cell carcinoma to ensure that the donor lung is not contaminated with residual bronchoalveolar cell carcinoma cells in the upper airways during surgical implantation. The rarity of lung transplantation for cancer, and the absence of head-to-head trials comparing lung transplantation with conventional cancer care, limit the conclusions that can be drawn about lung transplantation for this indication. Furthermore, the ethical balance of how to allocate a scarce resource, such as a donor lung, remains an unresolved dilemma given the uncertainties regarding long-term survival. Conversely, individual patients might have substantial increases in survival and quality of life equivalent or superior to conventional cancer treatment methods.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Glanville AR, Wilson BE. Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma. Lancet Oncol. 2018. PMID: 30084382. doi:10.1016/S1470-2045(18)30297-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。